Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et fase 2/3-studie for at evaluere sikkerheden og effektiviteten af ​​EIK1001-006 i kombination med Pembrolizumab versus placebo og Pembrolizumab som førstelinjebehandling hos patienter med avanceret melanom

2. oktober 2026 opdateret af: Eikon Therapeutics

En multicenter, randomiseret, dobbeltblind, aktiv komparator-kontrolleret, adaptiv fase 2/3-undersøgelse til evaluering af sikkerheden og effektiviteten af ​​EIK1001 og Pembrolizumab versus placebo og Pembrolizumab som førstelinjebehandling hos deltagere med avanceret melanom.

The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma. The study includes dose optimization and expansion parts.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

740

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Krishna Kaza, Director Clinical Study Management
  • Telefonnummer: +1 (516) 675-6163
  • E-mail: Kazak@eikontx.com

Studiesteder

    • New South Wales
    • Queensland
      • Chermside, Queensland, Australien, 4032
        • Rekruttering
        • Icon Cancer Centre Chermside
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Chun Gan
    • South Australia
      • Bedford Park, South Australia, Australien, 5042
        • Rekruttering
        • Southern Adelaide Local Health Network Incorporated Flinders Medical Centre
        • Ledende efterforsker:
          • Amitesh Roy
        • Kontakt:
        • Kontakt:
    • Victoria
      • Box Hill, Victoria, Australien, 3128
        • Rekruttering
        • Eastern Health
        • Kontakt:
        • Ledende efterforsker:
          • Phillip Parente
        • Underforsker:
          • Zhen R Siow
      • Frankston, Victoria, Australien, 3199
        • Rekruttering
        • Peninsula and South Eastern Haematology and Oncology Group
        • Ledende efterforsker:
          • Vinod Ganju
        • Kontakt:
      • Sint-Niklaas, Belgien, 9100
        • Rekruttering
        • Vitaz Primary Location
        • Ledende efterforsker:
          • Ines Deleu
        • Kontakt:
    • Antwerpen
      • Edegem, Antwerpen, Belgien, 2650
        • Rekruttering
        • Universitair Ziekenhuis Antwerpen
        • Ledende efterforsker:
          • Marika Rasschaert
        • Kontakt:
        • Kontakt:
        • Underforsker:
          • Timon Vandamme
    • Brussels Capital
    • Namur
      • Yvoir, Namur, Belgien, B-5530
        • Rekruttering
        • Centre Hospitalier Universitaire Universite Catholique de Louvain - Site Godinne
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Laurence Faugeras
        • Underforsker:
          • Quentin Gilliaux
    • Vlaams Brabant
      • Leuven, Vlaams Brabant, Belgien, 3000
        • Rekruttering
        • Universitair Ziekenhuis Leuven - Campus Gasthuisberg
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Oliver Bechter
        • Underforsker:
          • Patrick Schöffski
    • West-Vlaanderen
      • Kortrijk, West-Vlaanderen, Belgien, 8500
        • Rekruttering
        • Algemeen Ziekenhuis Groeninge - Campus Kennedylaan
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Veronique Buyse
        • Underforsker:
          • Tine Loyson
    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • Rekruttering
        • Sunnybrook Research Ins<tute
        • Ledende efterforsker:
          • Rossanna Pezo
        • Kontakt:
        • Kontakt:
        • Underforsker:
          • Teresa Petrella
    • Central Jutland
      • Aarhus, Central Jutland, Danmark, 8200
        • Suspenderet
        • Aarhus Universitetshospital
    • Nord Jutland
      • Aalborg, Nord Jutland, Danmark, 9000
        • Suspenderet
        • Aalborg University Hospital
    • Belfast
      • Belfast, Belfast, Det Forenede Kongerige, BT9 7AB
        • Rekruttering
        • Belfast City Hospital, Belfast Health and Social Care Trust
        • Kontakt:
        • Ledende efterforsker:
          • Bode Oladipo
    • England
      • London, England, Det Forenede Kongerige, SE1 9RT
        • Rekruttering
        • Guy's and St Thomas' NHS Foundation Trust
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Alvin Lee
      • London, England, Det Forenede Kongerige, W1G6AD
        • Rekruttering
        • Sarah Cannon Research Institute London
        • Ledende efterforsker:
          • Anja Williams
        • Kontakt:
        • Underforsker:
          • Elisa Fontana
    • Hampshire
      • Southampton, Hampshire, Det Forenede Kongerige, SO32 2DA
        • Rekruttering
        • University Hospital Southampton
        • Kontakt:
        • Ledende efterforsker:
          • Matthew Wheater
    • Oulu
      • Oulu, Oulu, Finland, 90230
        • Rekruttering
        • Oulu University Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Sanna Livanainen
    • Pirkanmaa
      • Tampere, Pirkanmaa, Finland, 33521
        • Rekruttering
        • Tampere University Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Tanja Skyttä
    • Uusimaa
      • Helsinki, Uusimaa, Finland, 00029
        • Rekruttering
        • Helsinki University Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Micaela Hernberg
    • Arizona
      • Chandler, Arizona, Forenede Stater, 85224
        • Rekruttering
        • Ironwood Cancer & Research Centers
        • Kontakt:
        • Ledende efterforsker:
          • Amikar Sehdev, MD
    • Arkansas
      • Hot Springs, Arkansas, Forenede Stater, 71913
        • Rekruttering
        • Genesis Cancer and Blood Institute
        • Ledende efterforsker:
          • Robert Muldoon
        • Kontakt:
    • California
      • Los Angeles, California, Forenede Stater, 90015
      • Santa Rosa, California, Forenede Stater, 95403
        • Rekruttering
        • Providence Medical Foundation
        • Ledende efterforsker:
          • David Park
        • Underforsker:
          • Natalie Valle
        • Kontakt:
    • Colorado
      • Colorado Springs, Colorado, Forenede Stater, 80909
        • Rekruttering
        • UCHealth Memorial Hospital Central
        • Kontakt:
        • Ledende efterforsker:
          • Stacey ParkerBrueggemann, MD
    • Delaware
    • Florida
      • Hialeah, Florida, Forenede Stater, 33013
      • Tamarac, Florida, Forenede Stater, 33321
        • Rekruttering
        • Florida Clinical Trials Group - Tamarac
        • Ledende efterforsker:
          • Chintan Gandhi
        • Kontakt:
        • Kontakt:
        • Underforsker:
          • Lauren Brito
    • Maryland
      • Bethesda, Maryland, Forenede Stater, 20817
        • Rekruttering
        • The Center for Cancer and Blood Disorders
        • Ledende efterforsker:
          • Victor Priego
        • Kontakt:
    • Missouri
      • Kansas City, Missouri, Forenede Stater, 64132
        • Rekruttering
        • MidAmerica Cancer Care
        • Ledende efterforsker:
          • Jaswinder Singh
        • Kontakt:
      • St Louis, Missouri, Forenede Stater, 63108
        • Rekruttering
        • Washington University School of Medicine in St. Louis
        • Ledende efterforsker:
          • George Ansstas
        • Kontakt:
        • Underforsker:
          • Nicole Chrisman
    • Ohio
      • Canton, Ohio, Forenede Stater, 44718
        • Rekruttering
        • Gabrail Cancer Center Research LLC
        • Ledende efterforsker:
          • Nashat Gabrail
        • Kontakt:
        • Underforsker:
          • Carmen Baldwin
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15232
        • Rekruttering
        • University of Pittsburgh Medical Center(UPMC)-Hillman Cancer Center
        • Ledende efterforsker:
          • Diwakar Davar, MD
        • Kontakt:
    • Texas
      • Sugar Land, Texas, Forenede Stater, 77479
        • Rekruttering
        • Patientcare Clinical Research
        • Ledende efterforsker:
          • Amir Rasheed
        • Kontakt:
        • Underforsker:
          • Jianwen Dong
      • Bordeaux, Frankrig, 33075
        • Rekruttering
        • Hospital Saint Andre
        • Kontakt:
        • Ledende efterforsker:
          • Caroline Dutriaux
    • Auvergne-Rhône-Alpes
      • Pierre-Bénite, Auvergne-Rhône-Alpes, Frankrig, 69495
        • Rekruttering
        • Centre Hospitalier Lyon-Sud
        • Ledende efterforsker:
          • Stéphane Dalle
        • Kontakt:
    • Boulogne
      • Boulogne, Boulogne, Frankrig, 92104
    • Isère
      • La Tronche, Isère, Frankrig, 38700
        • Rekruttering
        • Centre Hospitalier Universitaire Grenoble Alpes
        • Ledende efterforsker:
          • Julie Charles
        • Kontakt:
    • Lille Cedex
      • Lille, Lille Cedex, Frankrig, 59037
    • Marseille
      • Marseille, Marseille, Frankrig, 13385
        • Rekruttering
        • Hôpital La Timone
        • Kontakt:
        • Ledende efterforsker:
          • Caroline Gaudy
    • PACA
      • Nice, PACA, Frankrig, 06200
        • Rekruttering
        • Centre Hospitalier Universitaire (CHU) Nice
        • Kontakt:
        • Ledende efterforsker:
          • Henri Montaudie
    • Paris
      • Paris, Paris, Frankrig, 75018
        • Rekruttering
        • Hôpital Bichat AP-HP Université Paris Cité
        • Kontakt:
        • Ledende efterforsker:
          • Florence Brunet-Possenti
    • Pays de la Loire Region
    • Rouen
      • Rouen, Rouen, Frankrig, 76031
        • Rekruttering
        • CHU Rouen
        • Kontakt:
        • Ledende efterforsker:
          • Anne Benedicte Duval Modeste
    • Be'er Sheva
      • Beersheba, Be'er Sheva, Israel, 8410101
        • Rekruttering
        • Soroka medical center
        • Kontakt:
        • Ledende efterforsker:
          • Alexander Yakobson
    • Petach Tikva
      • Petah Tikva, Petach Tikva, Israel, 4941492
        • Rekruttering
        • Rabin Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Nethanel Asher
    • Ramat Gan
      • Ramat Gan, Ramat Gan, Israel, 5262100
        • Rekruttering
        • Ella Lemelbaum Institute for Immuno-Oncology and Melanoma
        • Kontakt:
        • Ledende efterforsker:
          • Ronnie Shapira-Frommer
        • Underforsker:
          • Raz Mutai
    • Tel Aviv
      • Tel Aviv, Tel Aviv, Israel, 6423906
        • Rekruttering
        • Tel Aviv Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Mor Miodovnik
    • Foggia
      • San Giovanni Rotondo, Foggia, Italien, 71013
        • Rekruttering
        • Ospedale Casa Sollievo Della Sofferenza
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Gabriele Di Maggio
        • Underforsker:
          • Antonella Centonza
    • Italy
      • Alessandria, Italy, Italien, 15121
        • Rekruttering
        • Azienda Ospedaliera Universitaria SS Antonio e Biagio e Cesare Arrigo
        • Ledende efterforsker:
          • Federica Grosso
        • Kontakt:
        • Kontakt:
        • Underforsker:
          • Delfanti Sara
      • Messina, Italy, Italien, 98039
        • Rekruttering
        • Ospedale San Vincenzo Taormina
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Francesco Ferraù
        • Underforsker:
          • Elena Torrisi
      • Milan, Italy, Italien, 20133
      • Modena, Italy, Italien, 41125
        • Rekruttering
        • AOU Policlinico di Modena
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Roberta Depenni
        • Underforsker:
          • Stefano Greco
      • Padova, Italy, Italien, 35128
      • Trento, Italy, Italien, 38123
        • Rekruttering
        • Azienda Provinciale per I Servizi Sanitari
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Sonia Brugnara
        • Underforsker:
          • Federico Sganzerla
    • Liguria
      • Genoa, Liguria, Italien, 16132
        • Rekruttering
        • IRCCS Ospedale Policlinico San Marino
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Francesco Spagnolo
        • Underforsker:
          • Andrea Boutros
    • Milano
      • Milan, Milano, Italien, 20132
        • Rekruttering
        • IRCCS Ospedale San Raffaele
        • Kontakt:
        • Ledende efterforsker:
          • Vincenzo Russo
    • Province of Bergamo
      • Bergamo, Province of Bergamo, Italien, 24125
        • Rekruttering
        • Humanitas Gavazzeni Bergamo
        • Kontakt:
        • Ledende efterforsker:
          • Laura Pala
    • The Marches
      • Ancona, The Marches, Italien, 60126
    • Tuscany
      • Siena, Tuscany, Italien, 53100
        • Rekruttering
        • UOC Immunoterapia Oncologica
        • Kontakt:
        • Ledende efterforsker:
          • Anna Maria Di Giacomo
    • Christchurch
      • Christchurch, Christchurch, New Zealand, 8011
        • Rekruttering
        • Christchurch Public Hospital
        • Kontakt:
        • Ledende efterforsker:
          • David Gibbs
    • New Zealand
      • Auckland, New Zealand, New Zealand, 1023
        • Rekruttering
        • Auckland City Hospital
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Gareth Rivalland, MD
    • Bodø
      • Bodø, Bodø, Norge, N-8005
        • Rekruttering
        • Nordland Hospital Trust
        • Kontakt:
        • Ledende efterforsker:
          • Bard Mannsaker
    • Oslo
      • Oslo, Oslo, Norge, 0310
        • Rekruttering
        • Oslo University Hospital - The Norwegian Radium Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Marta Nyakas
    • Oslofjord
      • Drammen, Oslofjord, Norge, 3004
        • Rekruttering
        • Drammen Hospital
        • Kontakt:
        • Underforsker:
          • Alina Carmen Porojnicu
    • Gdańsk
      • Gdansk, Gdańsk, Polen, 80-952
        • Rekruttering
        • Uniwersyteckie Centrum Kliniczne
        • Kontakt:
        • Ledende efterforsker:
          • Kamil Drucis
    • Konin
      • Konin, Konin, Polen, 62-500
        • Rekruttering
        • Prezychodnia Lekarska KOMED Roman Karaszewski
        • Ledende efterforsker:
          • Bogusława Karaszewska
        • Kontakt:
    • Siedlce
      • Siedlce, Siedlce, Polen, 08-110
        • Rekruttering
        • Mazowiecki Szpital Wojewódzki, Siedlckie Centrum Onkologii
        • Ledende efterforsker:
          • Lubomir Bodnar
        • Kontakt:
    • Silesian Voivodeship
      • Gliwice, Silesian Voivodeship, Polen, 44-102
        • Rekruttering
        • Maria Sklodowska-Curie Na;onal Research Ins;tute of Oncology, Gliwice Branch
        • Ledende efterforsker:
          • Wieslaw Bal
        • Kontakt:
        • Kontakt:
        • Underforsker:
          • Anna Kotas
    • Warsaw
      • Warsaw, Warsaw, Polen, 02-781
        • Rekruttering
        • Maria Sklodowska-Curie National Cancer Research Institute
        • Kontakt:
        • Ledende efterforsker:
          • Anna Czarnecka
    • Lisbon District
      • Lisbon, Lisbon District, Portugal, 1500-650
        • Rekruttering
        • Hospital da Luz Lisboa
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Gonçalo Fernandes
      • Lisbon, Lisbon District, Portugal, 1099-023
        • Rekruttering
        • IPO Lisboa
        • Kontakt:
        • Ledende efterforsker:
          • Patricia Pereira
    • Canton of Zurich
      • Zurich, Canton of Zurich, Schweiz, 8091
        • Rekruttering
        • Universitätsspital Zürich
        • Ledende efterforsker:
          • Egle Ramelyte
        • Kontakt:
        • Kontakt:
        • Underforsker:
          • Michele Welti
    • Chur
      • Chur, Chur, Schweiz, 7000
        • Rekruttering
        • Kantonsspital Graubünden
        • Kontakt:
        • Ledende efterforsker:
          • Roger von Moos
    • Belgrade
      • Belgrade, Belgrade, Serbien, 11000
        • Rekruttering
        • Military Medical Academy- Department of Oncology
        • Kontakt:
        • Ledende efterforsker:
          • Lidija Kandolf
      • Cadiz, Spanien, 11407
        • Rekruttering
        • University Hospital of Jerez
        • Kontakt:
        • Ledende efterforsker:
          • Regina Garcia Galindo
        • Underforsker:
          • Gloria Aguilera
    • A Coruña
      • Santiago de Compostela, A Coruña, Spanien, 15706
        • Rekruttering
        • Hospital Clínico de Santiago de Compostela
        • Kontakt:
        • Ledende efterforsker:
          • Teresa Curiel
        • Underforsker:
          • Alexandra Mosquera
    • Badalona
      • Badalona, Badalona, Spanien, 08916
        • Rekruttering
        • H. Germans Trias I Pujol (ICO-Badalona)
        • Kontakt:
        • Ledende efterforsker:
          • José Manzano
    • Barcelona
      • Barcelona, Barcelona, Spanien, 08028
        • Rekruttering
        • Hospital Universitari Dexeus
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Maria G Cao
        • Underforsker:
          • Josep S Ortega
      • Barcelona, Barcelona, Spanien, 08035
        • Rekruttering
        • Vall d' Hebron Institute of Oncology
        • Kontakt:
          • Alba Barrio
          • Telefonnummer: 8827 (+34) 93 254 34 50
          • E-mail: bbruno@vhio.net
        • Kontakt:
          • Núria Llansana
          • Telefonnummer: 5063 (+34) 93 254 3450
          • E-mail: nfarras@vhio.net
        • Ledende efterforsker:
          • Eva M Couselo
    • Cantabria
      • Santander, Cantabria, Spanien, 39008
        • Rekruttering
        • Hospital Universitario Marques de Valdecilla
        • Ledende efterforsker:
          • Marta García
        • Kontakt:
        • Underforsker:
          • Belen Caramelo
    • Cáceres
      • Cáceres, Cáceres, Spanien, 10003
    • Galicia
      • Lugo, Galicia, Spanien, 27003
        • Rekruttering
        • Hospital Universitario Lucus Augusti
        • Kontakt:
        • Ledende efterforsker:
          • Begona Campos Balea
    • Girona
      • Girona, Girona, Spanien, 17007
        • Rekruttering
        • Institut Català d'Oncologia Girona (ICO Girona)
        • Kontakt:
        • Kontakt:
        • Underforsker:
          • Anna Carbó
        • Ledende efterforsker:
          • Elisabet Bujons
    • Madrid
      • Madrid, Madrid, Spanien, 28007
        • Rekruttering
        • Hospital General Universitario Gregorio Marañón
        • Kontakt:
        • Ledende efterforsker:
          • IVAN MARQUEZ
      • Madrid, Madrid, Spanien, 28002
        • Rekruttering
        • GenesisCare Madrid - Hospital San Francisco de Asís
        • Kontakt:
        • Ledende efterforsker:
          • José Angel Garcia Cuesta
      • Madrid, Madrid, Spanien, 28050
        • Rekruttering
        • HM CIOCC
        • Kontakt:
        • Ledende efterforsker:
          • Juan Rodriguez Moreno
      • Usera, Madrid, Spanien, 28031
        • Rekruttering
        • Hospital 12 de Octubre
        • Kontakt:
        • Ledende efterforsker:
          • Guillermo De Velasco
    • Malaga
      • Málaga, Malaga, Spanien, 29011
        • Rekruttering
        • Hospital Regional Universitario
        • Kontakt:
        • Ledende efterforsker:
          • Miguel Angel Berciano
    • Murcia
      • Murcia, Murcia, Spanien, 30120
        • Rekruttering
        • Hospital Clinico Universitario Virgen de la Arrixaca
        • Kontakt:
        • Ledende efterforsker:
          • Pablo Fuentes
        • Underforsker:
          • Miguel Angel Moya
    • Málaga
      • Málaga, Málaga, Spanien, 29010
        • Rekruttering
        • Hospital Universitario Virgen de la Victoria
        • Kontakt:
        • Ledende efterforsker:
          • Manuel Zalabardo
    • Spain
      • Barcelona, Spain, Spanien, 8036
        • Rekruttering
        • Hospital Clinic Barcelona
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Ana Arance
        • Underforsker:
          • Maribel Marmol
    • Valencia
      • Valencia, Valencia, Spanien, 46009
        • Rekruttering
        • IVO - Fundacion Instituto Valenciano de Oncologia
        • Ledende efterforsker:
          • Maria Jose Juan Fita
        • Kontakt:
        • Kontakt:
        • Underforsker:
          • Eduardo Nagore
      • Valencia, Valencia, Spanien, 46010
        • Rekruttering
        • INCLIVA Instituto de Investigación Sanitaria
        • Underforsker:
          • Valentina Gambardella
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Ines G Barrallo
    • Gävleborg County
      • Gävle, Gävleborg County, Sverige, 801 88
        • Rekruttering
        • Gävle Sjukhus
        • Kontakt:
        • Ledende efterforsker:
          • Ilke Cikman
        • Underforsker:
          • Olga Del Val Munoz
    • Södermanland County
      • Stockholm, Södermanland County, Sverige, 17176
    • Eastern Cape
      • Port Elizabeth, Eastern Cape, Sydafrika, 6045
        • Rekruttering
        • Cancercare Port Elizabeth - Langenhoven Drive Oncology Centre
        • Kontakt:
        • Ledende efterforsker:
          • John Crockett
        • Underforsker:
          • Sakina Bawa
    • Gauteng
      • Pretoria, Gauteng, Sydafrika, 0002
        • Rekruttering
        • University of Pretoria, Steve Biko Academic Hospital
        • Ledende efterforsker:
          • Richard Khanyile
        • Kontakt:
      • Saxonwold, Gauteng, Sydafrika, 2196
        • Rekruttering
        • The Medical Oncology Centre of Rosebank
        • Kontakt:
        • Ledende efterforsker:
          • Bernardo Rapoport
    • KwaZulu-Natal
      • Richards Bay, KwaZulu-Natal, Sydafrika, 3900
        • Rekruttering
        • Abraham Oncology
        • Ledende efterforsker:
          • Smitha Abraham
        • Kontakt:
    • Pretoria
      • Pretoria, Pretoria, Sydafrika, 0084
        • Rekruttering
        • Curo Oncology
        • Kontakt:
        • Ledende efterforsker:
          • Rouchelle Marais-Nieman
    • Western Cape
      • Cape Town, Western Cape, Sydafrika, 7570
        • Rekruttering
        • Cape Town Oncology Trials
        • Ledende efterforsker:
          • Corlia Coetzee
        • Kontakt:
        • Kontakt:
        • Underforsker:
          • Johann Riedemann
      • George, Western Cape, Sydafrika, 6529
        • Rekruttering
        • TASK Eden
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Louis Botha
        • Underforsker:
          • Alista Easton
      • Daegu, Sydkorea, 41404
        • Rekruttering
        • Kyungpook National University Chilgok Hospital
        • Ledende efterforsker:
          • Soo Jung Lee
        • Kontakt:
        • Underforsker:
          • In Hee Lee
      • Seoul, Sydkorea, 03080
        • Rekruttering
        • Seoul National University Hospital
        • Ledende efterforsker:
          • Miso Kim
        • Kontakt:
        • Underforsker:
          • Seo Yoon Jang
    • Brno
      • Brno, Brno, Tjekkiet, 65653
        • Rekruttering
        • Masaryk Memorial Cancer Institute
        • Kontakt:
        • Ledende efterforsker:
          • Radek Lakomy
        • Underforsker:
          • Svatopluk Dobeš
    • Hradce Kralove
      • Sokolov, Hradce Kralove, Tjekkiet, 50009
        • Rekruttering
        • University Hospital Hradec Kralove
        • Ledende efterforsker:
          • Jindrich Kopecky
        • Kontakt:
      • Dresden, Tyskland, 01307
        • Rekruttering
        • University Hospital Carl Gustav Carus Dresden
        • Kontakt:
        • Ledende efterforsker:
          • Friedegund Meier
        • Underforsker:
          • Kathlen Hantsch
      • Erfurt, Tyskland, D-99089
      • Gera, Tyskland, 07548
        • Rekruttering
        • SRH Wald-Klinikum Gera GmbH
        • Ledende efterforsker:
          • Sabine Sell
        • Kontakt:
        • Kontakt:
        • Underforsker:
          • Anne Meinzenbach
      • Münster, Tyskland, 48157
    • Baden-Wurttemberg
      • Mannheim, Baden-Wurttemberg, Tyskland, 68167
        • Rekruttering
        • Universitätsmedizin Mannheim
        • Ledende efterforsker:
          • Jochen Utikal
        • Kontakt:
      • Tübingen, Baden-Wurttemberg, Tyskland, 72076
        • Rekruttering
        • Universitaetsklinikum Tuebingen (UKT)
        • Kontakt:
        • Ledende efterforsker:
          • Andreas Meiwes
    • Bavaria
      • Würzburg, Bavaria, Tyskland, 97080
        • Rekruttering
        • Klinik für Dermatologie, Venerologie und Allergologie
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Anja Gesierich
    • Erlangen
      • Erlangen, Erlangen, Tyskland, 91054
        • Rekruttering
        • University Hospital Erlangen
        • Kontakt:
        • Ledende efterforsker:
          • Carola Berking
    • Free and Hanseatic City of Hamburg
      • Martinsried, Free and Hanseatic City of Hamburg, Tyskland, 20246
        • Rekruttering
        • Universitätsklinik Hamburg Eppendorf
        • Ledende efterforsker:
          • Christoffer Gebhardt
        • Kontakt:
    • Leipzig
    • Lower Saxony
    • North Rhine-Westphalia
      • Minden, North Rhine-Westphalia, Tyskland, 32429
        • Rekruttering
        • Johannes Wesling Klinikum Minden
        • Kontakt:
        • Ledende efterforsker:
          • Ralf Gutzmer
    • RLP
    • Schleswig-Holstein
      • Kiel, Schleswig-Holstein, Tyskland, 24105
      • Lübeck, Schleswig-Holstein, Tyskland, 23538
        • Rekruttering
        • Universitätsklinikum Schleswig-Holstein - Campus Lübeck
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Evelyn Gaffal
    • State of Berlin
      • Berlin, State of Berlin, Tyskland, 10115
        • Rekruttering
        • Charite Department of Dermatology, Venereology and Allergology
        • Ledende efterforsker:
          • Thomas Eigentler
        • Kontakt:
      • Pécs, Ungarn, 7632
        • Rekruttering
        • University of Pécs
        • Kontakt:
        • Ledende efterforsker:
          • Zsuzsanna Lengyel
    • Budapest
      • Budapest, Budapest, Ungarn, 1122
        • Rekruttering
        • National Institute of Oncology
        • Kontakt:
        • Ledende efterforsker:
          • Timea Balatoni
    • Styria
      • Graz, Styria, Østrig, 8036
        • Rekruttering
        • Universitätsklinikum Graz
        • Kontakt:
        • Ledende efterforsker:
          • Ingrid Wolf
        • Underforsker:
          • Christiane Mutz-Rabl

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

To be eligible for inclusion in this study, participants must:

  • Be ≥ 18 years of age on the day of signing of informed consent.
  • Have a life expectancy of at least 3 months.
  • Have histologically or cytologically confirmed Stage 3 (unresectable) or Stage 4 metastatic melanoma per AJCC 8th ed. and be eligible for standard therapy with pembrolizumab.
  • Have at least 1 lesion with measurable disease at Baseline by CT or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by assessment of local site Investigator/radiologist.
  • Have known BRAF V600 mutation status or consent to BRAF V600 mutation testing per local institutional standards during the screening period
  • Have completed prior radiotherapy at least 2 weeks prior to study treatment administration.
  • Have an ECOG Performance Status of 0 to 1.
  • Have adequate organ and marrow function as defined by normal CBC, coagulation, serum chemistry and liver function tests on specimens collected within 10 days of treatment start.
  • Have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication (applies to women of childbearing potential [WOCBP]).
  • Be willing to use either 2 adequate methods of contraception, 1 adequate method plus a hormonal method of contraception, or be willing to abstain from heterosexual activity throughout the study (Visit 1 to 120 days after the last dose of study therapy; applies to WOCBP who are not menopausal for > 2 years, post-hysterectomy/oophorectomy, or surgically sterilized).
  • Agree to use an approved adequate contraceptive method throughout the study (Visit 1 to 120 days after the last dose of study therapy; applies to sexually active male participants with a partner who is WOCBP).
  • Be willing and able to provide written, informed consent for the study.

Exclusion Criteria:

A participant is excluded from the study if any of the following criteria apply:

  • Has melanoma of ocular origin.
  • Is currently enrolled in or has recently participated in a study of an IMP and received an IMP within 4 weeks or 5 half-lives (whichever is shorter) of administration of EIK1001 or placebo.
  • Prior to the 1St dose of EIK1001 or placebo, the prospective participant has received systemic therapy for advanced melanoma.
  • Note: prior adjuvant or neoadjuvant melanoma therapies (such as anti-PD-1 or anti CTLA 4 therapies or BRAF/MEK inhibitors) are permitted if all related AEs have either returned to Baseline or stabilized, with a minimum of 6 months between the last dose of prior therapy and documented disease progression.
  • Experienced a ≥ Grade 3 AE while receiving prior anti PD 1 therapy.
  • Has had major surgery (< 3 weeks prior to the first dose).
  • Has received a live-virus vaccination within 30 days of the first dose of study treatment.
  • Has a known history of prior malignancy, unless the participant has undergone potentially curative therapy with no evidence of disease recurrence for 5 years.
  • Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate if they are clinically stable for at least 4 weeks with no evidence of new or enlarging brain metastases. There must be no need for immunosuppressive doses of glucocorticoids for at least 2 weeks prior to study treatment administration.
  • There is a mean resting QTcF > 470 ms on triplicate electrocardiograms.
  • There is active autoimmune disease that has required systemic treatment in the past 2 years. The following autoimmune conditions are permitted: Type 1 diabetes, hypothyroidism (on hormone replacement), or- vitiligo, psoriasis and alopecia as long as no systemic treatment is required.
  • There is either chronic treatment with systemic steroids, other immunosuppressive medication, or either of these has been administered within 14 days of start of study treatment.
  • Note: Participants with asthma that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections are eligible. Steroid replacement for adrenal insufficiency is also permitted.
  • There is a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/ interstitial lung disease.
  • There are any active infections requiring therapy.
  • There is uncontrolled human immunodeficiency virus (HIV) infection. HIV-infected participants with well-controlled HIV may enroll.
  • There is a positive test result for hepatitis B virus (HBV) or HCV indicating presence of virus (it is expected that all participants will have been serologically tested for hepatitis B in advance of this study, with HBsAG, anti-HBc IgG, and anti-HBs as per ASCO 2020 Provisional Clinical Opinion [PCO] on universal Serologic testing for hepatitis B at the onset of anticancer therapy; screening should also include an anti-HCV test prior to start of cancer treatment:
  • There is a history or clinical evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study or interfere with the participant's participation for the full duration of the study
  • Known psychiatric or substance abuse disorder that would interfere with cooperation with study requirements.
  • There is a known history of regular illicit drug use and/or recent history (within the last year) of substance abuse (including alcohol).
  • Participant is pregnant, breastfeeding, or planning to conceive or father children within the projected duration of the study.
  • Participant is currently receiving medications known to be strong inhibitors or inducers of CYP3A4 and CYP1A2.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Arm 1

Participants in this arm will receive Placebo and Standard of Care (Pembrolizumab).

Pembrolizumab is a PD-1 inhibitor.

Eksperimentel: Arm 2

Participants in this arm will receive EIK1001 (selected dose 1) + Standard of Care (Pembrolizumab).

Pembrolizumab is a PD-1 inhibitor.

EIK1001 is a Toll-like receptor 7/8 (TLR 7/8) dual agonist.

Eksperimentel: Arm 3

Participants in this arm will receive EIK1001 (selected dose 2) + Standard of Care (Pembrolizumab).

Pembrolizumab is a PD-1 inhibitor.

EIK1001 is a Toll-like receptor 7/8 (TLR 7/8) dual agonist.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression Free Survival (PFS)
Tidsramme: up to 5 years

Progression-free survival (PFS) is defined as the time from the date of randomization to documented progressive disease per RECIST 1.1 by BICR or death due to any cause, whichever occurs first.

up to 5 years
Overall survival (OS)
Tidsramme: up to 5 years

Overall survival (OS) defined as the time from randomization to death due to any cause.

up to 5 years
Objective Response (OR) (Dose Optimization Only)
Tidsramme: up to 5 years

Objective Response (OR; defined as participants who demonstrate confirmed complete response [CR] or partial response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 as assessed by the Investigator) (Dose Optimization Only).

up to 5 years
Adverse Events (AEs) (Dose Optimization Only)
Tidsramme: up to 2.5 years

Adverse events (AEs), and discontinuation of study treatment due to an AE (Dose Optimization Only). An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

up to 2.5 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Adverse Events (AEs) and Discontinuation of study treatment due to any AE.
Tidsramme: up to 2.5 years

Adverse events (AEs), and discontinuation of study treatment due to any AE. An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

up to 2.5 years
Objective Response (OR)
Tidsramme: up to 5 years

Objective response (OR) is defined as the participants who demonstrate confirmed response (CR) or partial response (PR) according to RECIST 1.1 by BICR.

up to 5 years
Duration of Response (DOR).
Tidsramme: up to 5 years

Duration of Response (DOR) is defined as the time from the first documented evidence of complete response (CR) or partial response (PR) until disease progression or death due to any cause, whichever occurs first according to RECIST 1.1 by BICR.

up to 5 years
Progression Free Survival (PFS)
Tidsramme: up to 5 years

Progression Free Survival (PFS) according to RECIST 1.1 by Investigator.

up to 5 years
Objective Response (OR)
Tidsramme: up to 5 years

Objective Response (OR) according to RECIST 1.1 by Investigator.

up to 5 years
Duration of Response (DOR)
Tidsramme: up to 5 years

Duration of Response (DOR) according to RECIST 1.1 by Investigator

up to 5 years
Duration of Response (DOR) (Dose Optimization Only).
Tidsramme: up to 5 years

Duration of Response (DOR) per RECIST 1.1 by Investigator (Dose Optimization Only).

up to 5 years
Progression-free survival (PFS) per RECIST 1.1 by Investigator (Dose Optimization Only).
Tidsramme: up to 5 years

Progression-free survival (PFS) per RECIST 1.1 by Investigator (Dose Optimization Only).

up to 5 years
Overall survival (OS) (Dose Optimization Only)
Tidsramme: up to 5 years

Overall survival (OS) defined as the time from randomization to death due to any cause (Dose Optimization Only).

up to 5 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Studieleder: Etah Kurland, Eikon Therapeutics
  • Studieleder: Muaz Sadeia, Eikon Therapeutics

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. maj 2025

Primær færdiggørelse (Anslået)

1. december 2035

Studieafslutning (Anslået)

1. december 2040

Datoer for studieregistrering

Først indsendt

18. november 2024

Først indsendt, der opfyldte QC-kriterier

18. november 2024

Først opslået (Faktiske)

20. november 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. oktober 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • EIK1001-006
  • KEYNOTE-G04 (Anden identifikator: Merck Sharp & Dohme LLC)
  • MK-3475-G04 (Anden identifikator: Merck Sharp & Dohme LLC)

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .